Colon Cancer Clinical Trial

Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer

Summary

RATIONALE: The use of a CD-ROM may help patients with colorectal cancer or a family history of colorectal cancer make informed decisions about undergoing microsatellite instability (MSI) testing.

PURPOSE: This randomized clinical trial is studying an educational CD-ROM to see how well it works compared with standard informed consent to assist decision-making about MSI testing in patients with colorectal cancer or a family history of colorectal cancer.

View Full Description

Full Description

OBJECTIVES:

Primary

Compare the impact of standard informed consent vs a CD-ROM educational intervention on knowledge about microsatellite instability (MSI) testing in patients with colorectal cancer (CRC) or a family history of CRC.
Determine the impact of these interventions on patient satisfaction with the preparation to make a decision.

Secondary

Determine whether the CD-ROM educational intervention has a differential impact on satisfaction with the MSI test decision, difficulty making the MSI test decision, and decisional conflict, as well as on patients' attitudes about MSI testing and CRC (e.g., perceived benefits and barriers to having the MSI test, perceived risk for colorectal and related cancers, self-efficacy), on general and cancer-related distress, and on discussions with family members about the MSI test and familial CRC risk.
Assess whether demographic factors, disease/family history characteristics, family support for testing, and cancer-related distress moderate the impact of the intervention on satisfaction with and completeness of the informed consent process.

OUTLINE: This is a multicenter, pilot, study (part I) followed by a randomized study (part II).

Part I: The educational CD-ROM is developed over 9 months. Patients receive a pilot version of the CD-ROM and provide feedback regarding usability and content.

Part II: Patients are randomized to 1 of 2 arms.

Arm I: Patients complete a baseline interview and receive a standard informed consent for microsatellite instability (MSI) testing and a brief, standardized explanation of the MSI test.
Arm II: Patients complete a baseline interview and receive a standard informed consent for MSI testing and the educational CD-ROM developed in phase I.

All patients in part II (even those that did not consent to the MSI test) complete a follow-up survey at 2 weeks.

Tissue samples from patients are analyzed by immunohistochemistry and MSI assay (polymerase chain reaction) for MLH1 and MSH2.

PROJECTED ACCRUAL: A total of 184 patients will be accrued for this study.

View Eligibility Criteria

Eligibility Criteria

Patient or family member meeting 1 of the following revised Bethesda colorectal cancer (CRC) criteria:

Diagnosis of colon or rectal cancer at < 50 years of age
Diagnosis of > 1 CRC at one time in the past
Diagnosis of ≥ 1 CRC at different times
Diagnosis of CRC and any other hereditary nonpolyposis colorectal cancer (HNPCC)-related cancers
Diagnosis of CRC in ≥ 2 first-degree or second-degree relatives with HNPCC-related tumor and ≥ 1 cancer diagnosed at < 50 years of age
Diagnosis of CRC in ≥ 2 first- or second-degree relatives with HNPCC-related tumors, regardless of age

Diagnosis of CRC with pathologic features suggestive of microsatellite instability (MSI) and < 60 years of age

Patients with CRC meeting the Amsterdam criteria defined below are ineligible:
Three relatives with CRC with 1 being a first-degree relative of the other 2
Cases that span ≥ 2 generations
At least 1 CRC case diagnosed before 50 years of age

PATIENT CHARACTERISTICS:

Not specified

PRIOR CONCURRENT THERAPY:

Not specified

Study is for people with:

Colon Cancer

Estimated Enrollment:

239

Study ID:

NCT00450424

Recruitment Status:

Completed

Sponsor:

Fox Chase Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Helen F. Graham Cancer Center at Christiana Hospital
Newark Delaware, 19713, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Fox Chase Cancer Center - Philadelphia
Philadelphia Pennsylvania, 19111, United States

How clear is this clinincal trial information?

Study is for people with:

Colon Cancer

Estimated Enrollment:

239

Study ID:

NCT00450424

Recruitment Status:

Completed

Sponsor:


Fox Chase Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider